Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Works by Cooksey, Jennifer
Results: 3
1
2
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody targeting the DR5 receptor.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 5, p. 887, doi. 10.1007/s00280-015-2712-0
- By:
- Publication type:
- Article
3
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1187, doi. 10.1007/s10637-015-0278-7
- By:
- Publication type:
- Article